Amyloid-PET und Alzheimer-Diagnose

详细信息    查看全文

• 作者：Univ.-Prof. Dr. Peter Dal-Bianco
• 关键词：SchlüsselwörterAmyloid ; PET ; AD ; Prodromalstadium ; MCI ; Leichte kognitive Störung ; Alzheimer ; Diagnose
• 刊名：psychopraxis. neuropraxis
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：20
• 期：1
• 页码：20-22
• 全文大小：
• 刊物主题：Psychotherapy;
• 出版者：Springer Vienna
• ISSN：2197-9715
• 卷排序：20

文摘

Molecular imaging in Alzheimer’s disease (AD) has made it possible to detect human brain amyloid-beta (Aβ) and tau deposition in living patients using positron emission tomography (PET). It has improved our understanding of Aβ as an important and therapeutically targetable component of AD pathology (immunotherapy). While Aβ plaques are one of the defining pathologic features of AD, many otherwise normal elderly people have elevated levels of Aβ, as do patients with clinical syndromes other than AD. Therefore the clinical utility of amyloid PET requires careful considerations so that its role may be placed in the proper clinical context.